Vascular Diseases  >>  Zontivity (vorapaxar)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zontivity (vorapaxar) / Merck (MSD)
TRACER, NCT00527943 / 2006-002809-31: Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

Checkmark AHA 2013 - TRA.CER
Nov 2013 - Nov 2013: AHA 2013 - TRA.CER
Checkmark TRA.CER
Nov 2013 - Nov 2013: TRA.CER
Checkmark ESC 2013: TRA.CER
More
Terminated
3
12944
NA
Vorapaxar, SCH 530348, MK-5348, Placebo
Merck Sharp & Dohme LLC, Duke Clinical Research Institute
Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
07/11
07/11
MK-5348-015, NCT00526474 / 2006-002942-12: Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

Checkmark AHA 2013 - TRA 2°P-TIMI 50
Nov 2013 - Nov 2013: AHA 2013 - TRA 2°P-TIMI 50
Checkmark AHA 2013 - TRA2°P-TIMI 50
Nov 2013 - Nov 2013: AHA 2013 - TRA2°P-TIMI 50
Checkmark TRA2{degrees}P-TIMI 50
More
Completed
3
26449
NA
Vorapaxar, Placebo
Merck Sharp & Dohme LLC, The Thrombolysis in Myocardial Infarction Study (TIMI) Group
Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident, Peripheral Arterial Disease
12/11
12/11

Download Options